Slide 1: H1 2024 Results Presentation
Zircaix®-PET avid H1 2024 Results Presentation PSMA-PET negative 22 August 2024 ASX: TLX Illustration showing TLX250 binding to carbonic Credit: anhydrase UCLA IX and expanded internalisation access program
Slide 2: Disclaimer
Disclaimer This presentation should be read in conjunction with our most recent reports and announcements, including our risk factors, lodged with the Australian Securities Exchange (ASX) or on our website. The information contained in this presentation is not intended to be an offer for subscriptio
Slide 3: Presenters and Agenda
Presenters Agenda 01 Introduction and results summary Christian Behrenbruch Darren Smith 02 H1 2024 achievements Managing Director and Group Chief Financial Officer Group Chief Executive Officer 03 Financial results 04 Outlook David Cade Kyahn Williamson Group Chief Medical Officer SVP Investor Rela
Slide 4: H1 2024: Catalysts driving value creation
H1 2024: Catalysts driving value creation Major milestones delivered across therapeutics, precision medicine and manufacturing Positive data for Growth opportunities Building depth in supply prostate cancer therapy across precision medicine chain and manufacturing • Positive data from ProstACT • Sig
Slide 5: H1 2024 achievements align to our strategy
H1 2024 achievements align to our strategy Our mission is to be the global leader in theranostic radiopharmaceuticals Progress late-stage Advance next generation Expand commercial Vertically integrate therapeutic pipeline of alpha theranostics imaging portfolio supply chain 5
Slide 6: H1 2024: Financial highlights
H1 2024: Financial highlights Improved profitability while investing for future growth Revenue Gross margin Cash balance as at 30 June 2024 growth 65% YOY improved $118.8M 66% vs $123.2M 31 Dec 2023 (63% H1 2023) $635M net proceeds from convertible bond issue1 will be reflected in H2 2024 Adjusted E
Slide 7: H1 2024 achievements
H1 2024 achievements Illustration showing TLX250 binding to carbonic anhydrase IX and internalisation
Slide 8: Late-stage therapeutic programs
Late-stage therapeutic programs Data readouts in prostate cancer programs, key milestones ahead for kidney and brain Prostate Kidney (CAIX2) Brain TLX591 and TLX592 TLX250 TLX101 • TLX591: Positive efficacy data • Multiple Phase II trials of • First peer-reviewed manuscript of from ProstACT SELECT -
Slide 9: Precision medicine (diagnostics)
Precision medicine (diagnostics) Focus on expansion of commercial portfolio and global rollout of Illuccix® Prostate Kidney (CAIX) Brain Illuccix® & TLX007-CDx Zircaix®4 (TLX250-CDx) Pixclara®4 (TLX101-CDx) • Novel PSMA1 imaging candidate • BLA5 resubmission expected • Granted Fast Track designation
Slide 10: Delivering innovation in PSMA-PET imaging
Delivering innovation in PSMA-PET imaging Maintaining competitive advantage and maximising customer choice Telix PSMA ⚫ Broadest patient reach in the U.S. Illuccix + product strategy TLX007-CDx will expand geographic coverage to all available PET cameras ⚫ Addresses inequity in PSMA-PET imaging avai
Slide 11: Building depth in supply chain and manufacturing
Building depth in supply chain and manufacturing Bolstered by recent acquisitions and investment, Brussels South advancement Enhanced in-house capability and production Global production, process development capacity, supply chain control and R&D footprint • ARTMS: Advanced isotope production platfo
Slide 12: Financial results
Financial results €) Telix
Slide 13: Commercial performance
Commercial performance Illuccix® increasing share in the growing U.S. market • Revenue up 65% in H1 2024, majority of group revenue generated from U.S. sales Revenue of Illuccix® Group revenue guidance AU$M / US$M H1 2024 • Dose volume / demand continues to 412.0 US$270.4 increase quarter on quarter
Slide 14: Revenue growth and cost control drives improved profitability
Revenue growth and cost control drives improved profitability Group profit and loss statement Half year • Strategic allocation of capital towards H1 2024 % of H2 2023 % of H1 2023 % of growth initiatives, while balancing cost $M revenue $M revenue $M revenue control, sees operating costs decline as
Slide 15: Profit contribution from commercial operations
Profit contribution from commercial operations Adjusted EBITDAR1 reflects underlying commercial profitability • Adjusted EBITDAR continues to grow as a H1 2024 % of H1 2023 % of percentage of revenue, demonstrating the $M revenue $M revenue Group’s ability to self-fund significant product developmen
Slide 16: Sustaining operating cash flow
Sustaining operating cash flow H1 2024 operating cash sustains investment in future growth Cash reconciliation • Commercial operations earnings AU$M / US$M* effectively invested to fund core 343.3 therapeutic and precision medicine pipeline development • Improved customer receipts reflect sales grow
Slide 17: H1 2024 R&D summary
H1 2024 R&D summary Focused investment aligned with strategic priorities H1 2024 R&D investment • R&D investment in line with guidance and tracking to plan 8% • R&D focus areas include: 23% • Late-stage diagnostic assets: regulatory 41% submissions, filing fees, expanded access $83.9M programs • The
Slide 18: Outlook
Outlook Illustration showing TLX300 binding to platelet derived growth factor receptor alpha
Slide 19: Building momentum for future value creation
Building momentum for future value creation Strengthened balance sheet provides flexibility to deliver on our strategic priorities Progress late-stage Advance next generation Expand commercial Vertically integrate therapeutic pipeline of alpha theranostics imaging portfolio supply chain • Complete P
Slide 20: Pipeline expansion: New programs moving into the clinic
Pipeline expansion: New programs moving into the clinic TARGETING Dx/ ISOTOPE PRE-CLINICAL PHASE I PHASE II PHASE III COMMERCIAL AGENT Tx4 Antibody 177Lu Tx TLX591 (177Lu rosopatamab tetraxetan) Antibody 225Ac (alpha) Tx Prostate TLX592 (225Ac-RADmAb®) PSMA1 Small molecule 68Ga Dx Illuccix® (68Ga-PS
Slide 21: Precision medicine presents a near-term growth opportunity
Precision medicine presents a near-term growth opportunity Label expansion studies will facilitate expedited access to expanded market Prostate cancer Kidney cancer Brain cancer Total U.S. market opportunity Current approved prostate Diagnosis of ccRCC3, For imaging of glioma, cancer imaging agent t
Slide 22: Our unique radiopharma ecosystem
Our unique radiopharma ecosystem Optimised for radiopharma development and commercialisation Four business units, aligned to core mission of delivering therapeutic radiopharmaceuticals, Precision Medicine underpinned by precision oncology (Px) • Therapeutics: Core focus, major growth opportunity - d
Slide 23: Delivering to our strategy
Delivering to our strategy Multiple near-term catalysts ahead Progress late-stage Advance next generation Expand commercial Vertically integrate therapeutic pipeline of alpha theranostics imaging portfolio supply chain 2024 H1 2025 Illuccix® Brazil, EU and UK approval ProstACT GLOBAL (TLX591) Ph III
Slide 24: Contact details
Contact details: Kyahn Williamson SVP Investor Relations and Corporate Communication kyahn.williamson@telixpharma.com